Tsung-Ying Li

Tsung-Ying Li

Auto-generated profile, based on publicly available information

Tsung-Ying Li

Department of Physical Medicine and Rehabilitation, Tri-Service General Hospital, National Defense Medical University, Taipei City, Taiwan

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2019 in Journal of Tissue Engineering and Regenerative Medicine
Verified
Journal Article
Closed access
PDF file
YSYu-Ping Shen
Yu-Ping Shen
TLTsung‐Ying Li
Tsung‐Ying Li
YCYu‐Ching Chou
Yu‐Ching Chou
THTsung‐Yen Ho
Tsung‐Yen Ho
MKMing‐Jen Ke
Ming‐Jen Ke
YWYung-Tsan Wu
Yung-Tsan Wu

Verified
Journal Article
Open access
PDF file
Ta-Chung ChaoTa-Chung Chao
Ta-Chung Chao
KRKenneth Dean Reeves
Kenneth Dean Reeves
King Hei Stanley LamKing Hei Stanley Lam
King Hei Stanley Lam
TLTsung-Ying Li
Tsung-Ying Li
YWYung-Tsan Wu
Yung-Tsan Wu
Patients with failure of primary surgery for carpal tunnel syndrome (CTS) present a frustrating clinical problem because there are no relevant treatment guidelines, and the effect of current conservative management or revision surgery is unsatisfactory. Hydrodissection with 5% dextrose is emerging as an effective treatment for primary CTS and may be an effective alternative treatment method for persistent or recurrent post-surgical CTS. We retrospectively investigated the long-term effectiveness of hydrodissection with 5% dextrose for persistent or recurrent CTS. Thirty-six of forty consecutively-treated patients with either persistent or recurrent symptoms of CTS after surgery, who were treated with ultrasound-guided hydrodissection of the median nerve using 10 mL of 5% dextrose, were available to provide outcome data by a structured phone interview at least six months after treatment completion. Symptom relief ≥ 50% represented an effective outcome, while symptom relief < 50% was rated as a poor outcome. Nearly 2/3 (61.1%) of patients reported an effective outcome after a mean of 3.1 injections, with a post-injection follow-up mean of 33 (6–67) months. A non-significant trend toward a more frequently-effective outcome was observed in those with recurrent versus persistent symptoms following CTS (76.9% vs. 52.2%, p = 0.165). However, a significantly higher percentage of those with recurrent symptoms reported an excellent outcome, defined as a greater than 70% improvement (8/13 [61.6%] vs. 3/23 [13%], p = 0.006). The percentage of patients achieving an effective outcome was not significantly different between 4 years of post-treatment follow-up (36.4% vs. 77.8% vs. 57.1%; p = 0.077). Hydrodissection with 5% dextrose may result in a clinically important and durable benefit in those experiencing persistent or recurrent CTS after surgery.

13 March 2019 in Haemophilia
Verified
Journal Article
Closed access
PDF file
TLTsung‐Ying Li
Tsung‐Ying Li
YWYung‐Tsan Wu
Yung‐Tsan Wu
LCLiang‐Cheng Chen
Liang‐Cheng Chen
SCShin‐Nan Cheng
Shin‐Nan Cheng
RPRu‐Yu Pan
Ru‐Yu Pan
YCYeu-Chin Chen
Yeu-Chin Chen

19 January 2022 in Pain Medicine
Verified
Journal Article
Closed access
PDF file
CLChia-Ying Lai
Chia-Ying Lai
TLTsung-Ying Li
Tsung-Ying Li
King Hei Stanley LamKing Hei Stanley Lam
King Hei Stanley Lam
YCYu-Ching Chou
Yu-Ching Chou
Dueng-Yuan HuengDueng-Yuan Hueng
Dueng-Yuan Hueng
YWYung-Tsan Wu
Yung-Tsan Wu
Interest in perineural platelet-rich-plasma (PRP) injections for the treatment of carpal tunnel syndrome (CTS) has increased in recent years. However, evidence supporting the long-term effectiveness of PRP is lacking. Therefore, the aim of our cross-sectional cohort study was to investigate the long-term results of PRP injections for CTS. Eighty-one patients diagnosed with CTS of any grade who received a single PRP injection at least 2 years prior were enrolled. Through structured telephone interviews, all patients were asked of their post-injection outcomes compared to their pre-injection condition. Symptom relief ≥50%, compared to the pre-injection condition, was considered an effective outcome. Binary logistic regression was applied to analyze each baseline variable as a regressor for determining the prognostic outcome factors. In total, 70% of patients reported positive outcomes ≥2 years post-injection. Shorter duration of symptoms before treatment (odds ratio: 0.991; 95% confidence interval [CI] 0.983–0.999; P = .023) and lower electrodiagnostic severity of CTS were the main prognostic factors for an effective outcome (mild grade vs severe grade, odds ratio: 17.652; 95% CI 1.43–221.1; P = .025). Although there was a trend toward positive outcomes at longer follow-up durations (2–3 years vs 3–4 years vs 4–5 years), the difference was not statistically significant. A single perineural PRP injection has a long-term analgesic effect on CTS, especially in mild-to-moderate cases.

Verified
Journal Article
Open access
PDF file
YWYung-Tsan Wu
Yung-Tsan Wu
TLTsung-Ying Li
Tsung-Ying Li
KLKuei-Chen Lee
Kuei-Chen Lee
King Hei Stanley LamKing Hei Stanley Lam
King Hei Stanley Lam
CCCHIH-YA CHANG
CHIH-YA CHANG
LCLiang-Cheng Chen
Liang-Cheng Chen
Recent studies have suggested that the combined injection of platelet-rich plasma (PRP) and hyaluronic acid (HA) may have additive benefits for knee osteoarthritis over PRP alone, but there is insufficient evidence to support this combined injection. Moreover, the simultaneous injection of PRP and HA may offset the combined effect. Hence, the aim of this prospective, randomized, double-blind study was to assess their combined efficacy with a novel injection protocol. Forty-six study subjects with unilateral knee osteoarthritis were randomized to receive either a single-dose injection of HA (intervention group) or normal saline (control group) 1 week after a single-dose injection of leukocyte-poor PRP. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and static balance and the risk of falls measured by Biodex Balance System were, respectively, the primary and secondary outcome measures. Evaluations were performed at baseline, 1 month, 3 months, 6 months, and 12 months post-injection. The intervention group exhibited significant declines in WOMAC pain, stiffness, and total scores, as well as static balance, compared to the control group (p < 0.05). These randomized double-blind control trials, with novel protocol of intra-articular injection of PRP 1-week prior to HA, provide greater symptom relief and improve static balance compared to PRP alone in patients with knee osteoarthritis.

1 January 2022 in BioMed Research International
Verified
Journal Article
Open access
PDF file
YWYung-Tsan Wu
Yung-Tsan Wu
King Hei Stanley LamKing Hei Stanley Lam
King Hei Stanley Lam
CLChia-Ying Lai
Chia-Ying Lai
SCSi-Ru Chen
Si-Ru Chen
YSYu-Ping Shen
Yu-Ping Shen
CWChueh-Hung Wu
Chueh-Hung Wu
Nerve hydrodissection uses fluid injection under pressure to selectively separate nerves from areas of suspected entrapment; this procedure is increasingly viewed as potentially useful in treating carpal tunnel syndrome (CTS). The usage of normal saline (NS), 5% dextrose water (D5W), platelet‐rich plasma (PRP), and hyaluronic acid (HA) as primary injectates for hydrodissection without an anesthetic can limit anesthetic‐related toxicity and preserve the motor functions of the median nerve. Here, we describe a novel motor‐sparing neural injection and compare the effect of these four injectates for severe CTS. We retrospectively reviewed the outcomes of 61 severe CTS cases after a single neural injection with NS, D5W, PRP, or HA. Outcomes were evaluated on the 1st and 6th months postinjection, including the Boston Carpal Tunnel Questionnaire (BCTQ) scores and the nerve cross‐sectional area (CSA). The results revealed that PRP, D5W, and HA were more efficient than NS at all measured time points (p < 0.05), except for CSA at the 1st month between the NS and D5W groups. Single‐injections of PRP and D5W seemed more effective than that of HA within 6 months postinjection for symptom and functional improvement (6th‐month BCTQ‐symptom, D5W vs. HA, p = 0.047; 1st‐month BCTQ‐symptom, PRP vs. HA, p = 0.018; 1st‐ and 6th‐month BCTQ‐function, D5W vs. HA, p = 0.002 and 0.016, respectively; 1st‐month BCTQ‐function, PRP vs. HA, p < 0.001). For reducing CSA, PRP and HA seemed more effective than D5W (HA > PRP > D5W on the 1st month and HA vs. D5W, p = 0.001; PRP > HA > D5W on the 6th month and PRP vs. D5W, p = 0.012).